nayan patel glutathione Episode 85 Featuring World Renown Expert Dr. Patel! Get ready to become a full blown expert on everything Glutathione! Last year at A4M, I was heading to see a speaker 454: Nayan Patel | Unlocking

Key findings include: GLP3 monotherapy achieved 22.8-24.2% mean weight reduction at 48 weeks in phase 2 obesity trials (8-12 mg doses) Cagrilintide monotherapy produced 10.8% weight loss over 26 weeks in phase 2 studies (2.4 mg dose) CagriSema combination (cagrilintide + semaglutide) achieved 20.4% weight loss at 68 weeks in phase 3 REDEFINE trials Combination approaches consistently outperformed single-agent therapies across multiple dose ranges Studies demonstrated that 100% of participants receiving GLP3 8 mg or higher achieved at least 5% weight loss, with 75-83% achieving 15% or greater weight reduction[9]

For 5-amino-1MQ specifically: Preclinical studies have not prominently described heart rate elevation as a dominant signal The mechanism (NNMT inhibition, NAD+ preservation) does not have the same direct cardiac implications as nuclear receptor agonism Human cardiovascular data at clinically relevant exposures are limited For physicians, the current evidence base does not support a major cardiovascular safety flag, but the limited human dataset means confident statements are premature

Slower gastric emptying also means timing and meal size matter, and we coach patients through both

Though not currently approved for human use, the MOTS-C peptide is becoming popular for its energy-boosting effect and is often part of peoples longevity or metabolic health stacks

Avoiding toxicity As the saying goes, too much of anything is a bad thing